Taylor, Sophia ORCID: https://orcid.org/0000-0002-3116-5647, Weyinmi, Demeyin, Muls, Ann, Ferguson, Catherine, Farnell, Damian J. J. ORCID: https://orcid.org/0000-0003-0662-1927, Cohen, David, Andreyev, Jervoise, Green, John, Smith, Lesley, Ahmedzai, Sam, Pickett, Sara, Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425 and Staffurth, John Nicholas ORCID: https://orcid.org/0000-0002-7834-3172 2016. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. British Medical Journal Open 6 (10) , e011773. 10.1136/bmjopen-2016-011773 |
Preview |
PDF (PDF; Gold Access Enabled.)
- Published Version
Available under License Creative Commons Attribution Non-commercial. Download (2MB) | Preview |
Abstract
Introduction: Radiotherapy treatment for prostate cancer can cause bowel problems, which may lead to severe difficulties for cancer survivors including limiting travel, work or socialising. These symptoms can appear at any time following radiotherapy. This study focuses on the early identification and protocol-based management of effects known to cause long-term, or even permanent, changes to the well-being of prostate cancer survivors. The rationale of this study is to improve the care offered to men and their families following pelvic radiotherapy for prostate cancer. Method and analysis: Implementation research methodology will be used to adopt a multicomponent intervention at three UK centres. The intervention package comprises a standardised clinical assessment of relevant symptoms in oncology outpatient clinics and rapid referral to an enhanced gastroenterological service for patients identified with bowel problems. Gastroenterology staff will be trained to use an expert practice algorithm of targeted gastroenterology investigations and treatments. The evaluation of the intervention and its embedding within local practices will be conducted using a mixed-methods design. The effect of the new service will be measured in terms of the following outcomes: acceptability to staff and patients; quality of life; symptom control and cost effectiveness. Data collection will take place at baseline, 6 months (±2 months), and 12 months (±2 months) after entry into the study. Ethics and dissemination: The study has ethical approval from the North West-Liverpool East Research Ethics Committee and the appropriate NHS governance clearance. All participants provide written informed consent. The study team aim to publish the results of the study in peer-reviewed journals as well as at national and international conferences. Trial registration number: UKCRN16974
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Dentistry Medicine |
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Publisher: | British Medical Journal Publishing Group |
ISSN: | 2044-6055 |
Funders: | Prostate Cancer UK’s True NTH initiative, Marie Curie Cancer Care core grant funding MCCC-FCO-14-C |
Date of First Compliant Deposit: | 14 October 2016 |
Date of Acceptance: | 20 June 2016 |
Last Modified: | 04 Jan 2024 08:42 |
URI: | https://orca.cardiff.ac.uk/id/eprint/95336 |
Citation Data
Cited 8 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |